Ahn, J.H.; Choi, S.B.; Park, J.M.; Kim, J.Y.; Park, H.S.; Kim, S.I.; Park, B.-W.; Park, S.
Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients. Cancers 2021, 13, 5007.
https://doi.org/10.3390/cancers13195007
AMA Style
Ahn JH, Choi SB, Park JM, Kim JY, Park HS, Kim SI, Park B-W, Park S.
Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients. Cancers. 2021; 13(19):5007.
https://doi.org/10.3390/cancers13195007
Chicago/Turabian Style
Ahn, Jee Hyun, Soon Bo Choi, Jung Min Park, Jee Ye Kim, Hyung Seok Park, Seung Il Kim, Byeong-Woo Park, and Seho Park.
2021. "Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients" Cancers 13, no. 19: 5007.
https://doi.org/10.3390/cancers13195007
APA Style
Ahn, J. H., Choi, S. B., Park, J. M., Kim, J. Y., Park, H. S., Kim, S. I., Park, B.-W., & Park, S.
(2021). Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients. Cancers, 13(19), 5007.
https://doi.org/10.3390/cancers13195007
